Initiator Pharma signs screening agreement with the US National Institute on Drug Abuse to evaluate anti-addictive properties of preclinical assets
PRESS RELEASE September 17, 2021 Initiator Pharma A/S, a clinical-stage Life Science company, today announced that it has signed a screening agreeement with the National Institute on Drug Abuse (NIDA) in the USA in order to investigate the potential benefits of the company’s preclinical assets IPDP2015 and IPNP2015 for improved treatment of addiction.Initiator Pharma has signed a screening agreement with the National Institute on Drug Abuse (NIDA), www.nida.nih.gov, part of the National Institutes of